Kodiak Shares Climb Following Positive Results From Late-Stage Retina Disease Study

 Kodiak Sciences Inc. 

KOD+14.1%+ Free Alerts

 announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion.

The Phase 3 BEACON study is designed to evaluate the durability, efficacy and safety of tarcocimab tedromer in patients with treatment-naïve macular edema due to retinal vein occlusion.

The Phase 3 study met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept and demonstrated robust anatomic responses and a favorable safety profile.

Victor Perlroth, Chief Executive Officer, commented: “Our regulatory strategy is designed to have two successful studies in one indication and then individual studies in additional indications. Looking across our development program for tarcocimab, our paired Phase 3 GLEAM and GLIMMER studies in DME, if successful, are designed to serve as the primary basis for a licensing application and potential regulatory approval of tarcocimab.”

The company is expected to present primary results from the BEACON study at upcoming ophthalmology congresses in September 2022.

https://www.benzinga.com/general/biotech/22/08/28398943/kodiak-shares-climb-following-positive-results-from-late-stage-retina-disease-study